Company profile for MiNK Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, i...
MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, innate and adaptive. iNKTs combine the killing features of natural killer (NK) cells with the durable memory response of T cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
149 Fifth Avenue Suite 500 New York, NY 10010
Telephone
Telephone
212.994.8250
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/20/3192212/0/en/MiNK-Therapeutics-Announces-New-Data-Showing-MiNK-215-Drives-Potent-Anti-Tumor-Activity-in-Treatment-resistant-Solid-Tumors.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188228/0/en/MiNK-Therapeutics-Reports-Q3-2025-Results-and-Accelerates-iNKT-Platform-Toward-Pivotal-Development-Across-Oncology-Pulmonary-Disease-and-Transplantation.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183675/0/en/MiNK-Therapeutics-Reports-Durable-Responses-and-Immune-Reactivation-with-Allo-iNKT-Cell-Therapy-agenT-797-in-PD-1-Refractory-Solid-Tumors-at-SITC-2025.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181582/0/en/MiNK-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results-and-Highlight-Clinical-and-Corporate-Milestones-Advancing-iNKT-Platform-Toward-Pivotal-Development.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177489/0/en/MiNK-Therapeutics-to-Present-Late-Breaking-Data-on-AgenT-797-in-Solid-Tumors-at-the-40th-Annual-Society-for-Immunotherapy-of-Cancer-SITC-Meeting.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/09/29/3157608/0/en/MiNK-Therapeutics-Appoints-Colonel-Ret-John-B-Holcomb-MD-to-Board-of-Directors.html

GLOBENEWSWIRE
29 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty